Macrocytic Anemia With Vitamin B12 DeficiencyNCT04027959
Transdermal Iontophoresis of Vitamin B12 Under Three Different Skin Preparations
A study testing Vitamin B12 in people with Macrocytic Anemia With Vitamin B12 Deficiency, run by James J. Peters Veterans Affairs Medical Center at 1 site in United States.
Trial summary
STUDY DESIGN: Phase I Clinical Trial The researchers set out to assess the effectiveness of transdermal iontophoretic administration of Vitamin B12 (V.B12) under three different skin preparatory conditions. SETTING: James J. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Macrocytic Anemia With Vitamin B12 Deficiency
- What is being tested?
- Vitamin B12
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Oct 2017to 1 Nov 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Able-bodied,
- Male or female,
- Between the ages of 18-80 years old.
Who cannot join
- Previous adverse reaction or hypersensitivity to electrical stimulation,
- Pregnancy (women who are sexually active and of childbearing potential must utilize a method of contraception and agree to maintain a contraceptive method until completion of the study),
- Inability to provide informed consent,
- History of ingrown hair folliculitis after shaving or epilation,
- Allergy to Sodium Lauryl Sulfate, Oleic acid, Silver Chloride, Agarose Gel, Methylcobalamin, Citric Acid, Isopropyl alcohol, Benzocaine, Polyethylene film, Polyethylene Glycol solvent,
- Concurrent illness with fever,
- Concurrent participation in a research study,
- VA employee.
Trial locations and contacts
1 site in 1 country.
United States1 site
James J Peters VA Medical Center
The Bronx, New York, 10468
About this study
Official title: Novel Skin Preparation Approaches for Transdermal Delivery by Iontophoresis of a Low Molecular Weight, Positively Charged Compound (Vitamin B12) to the Systemic Circulation
STUDY DESIGN: Phase I Clinical Trial The researchers set out to assess the effectiveness of transdermal iontophoretic administration of Vitamin B12 (V.B12) under three different skin preparatory conditions.
SETTING: James J. Peters Veterans Affairs Medical Center (Bronx, NY) BACKGROUND: Poor skin permeability precludes the use of transdermal route from being used in common clinical practice for rapid and precise administration of medications through intact skin that are expected to have a systemic effect. The researchers determined the relative effectiveness of an unconventional transdermal iontophoresis technique for the administration of Vitamin B12 (V.B12) under three different skin preparatory conditions.
METHODS: During this study, Vitamin B12 (V.B12) was administered through the skin of volunteer human research subjects. Iontophoresis was used as transdermal medication delivery modality after pre-treatment of the skin in 3 different ways. The sequence of skin preparations was arranged in a random order for each subject. Method 1 was called "No Prep", serving as the control approach; method 2 was called "Oleic Acid" application to the skin for 40 minutes; and method 3 was hair "Epilation" (e.g. hair removal by plucking). Fifteen milligrams of aqueous solution of V.B12 was administered through intact, previously unused skin of an anterior thigh during all 3 tests. Chemoluminescence, on an automated laboratory reader Advia Centaur-XP, was used to determine the serum concentration of V.B12 prior to and after transdermal iontophoretic delivery. All 3 experiments were performed on the same day within an hour of each other. The subject's blood was drawn prior and 10 minutes after the 20-minute long sessions of transdermal V.B12 iontophoresis. We were able to calculate the increase in serum V.B12 concentration and based on estimated blood volume, the total quantity and percent dose delivered systemically.
Read the detailed description
In order to quantify the changes in skin permeability to drugs delivered by ION under three different preparatory conditions, we used V.B12 as a model substance. Its choice was dictated by its inherent safety, positive charge and quantification of serum concentration readily available through our clinical laboratory. We compared the effects of unprepared skin (No Prep), oil-soaked skin [ref. 9-12] (Oleic Acid) and skin from which hair have been plucked out of (Epilation), on the serum concentrations of V.B12 before and after administration via ION.
Veterans and non-Veterans without SCI were recruited for the study comparing the three skin preparation methods. This prospective, skin preparatory method sequence-randomized study was approved by the Institutional Review Board of the James J. Peters VA Medical Center (JJPVAMC). The ION equipment used was a standard FDA-approved wired ION controller unit (IBOX by Dynatronics) and 4mL ION electrodes by (ionto+ by Richmar). The skin was prepared using 1 of the 3 techniques, performed in a random order. Each subject was assigned a 2-digit sequential number. A random-numbers table was used to assign the sequence of methods to each subject. A single positive electrode patch containing 4mL of a water-based solution with 15mg of V.B12 was used per experiment. One negative electrode patch was also used to complete the circuit. Blood was drawn prior to the first administration. Thirty minutes after the start of the ION delivery of the V.B12 through the skin of anterior thigh, the blood was drawn again. The blood was centrifuged for 5 minutes and delivered to the clinical laboratory for testing without delay. Serum concentration of V.B12 was measured using chemoluminescence on an automated laboratory reader Advia Centaur-XP. The experiments were conducted sequentially in a timely fashion, performed on the same day and within a span of 3 hours. Blood was drawn for a total of 4 times per subject.
The "No Prep" technique was performed by simply wiping the two skin surfaces on an anterior thigh, where the electrodes were later attached, with two-70% isopropyl alcohol prep. pads. The skin surface destined for positive electrode application was sprayed with a thin layer of 20% Benzocaine (Americaine aerosol spray can) and covered with an occlusive plastic film for 10 minutes. The film was then removed and the skin was cleansed with water-moistened paper towel, followed by one alcohol prep. pad.
The "Oleic Acid" technique involved first wiping the two skin patches and later soaking the skin patch, where the positive electrode was going to be placed, with oil called oleic acid for 40 minutes. The oil was then wiped off with a paper napkin and an alcohol pad. That same skin area was sprayed with a thin layer of 20% Benzocaine (Americaine aerosol spray container) and covered with an occlusive plastic film for 10 minutes. The film was then removed and the skin was cleansed with water-moistened paper towel, followed by one alcohol prep.
The "Hair Epilation" technique involved first wiping the two skin patches with 2-70% isopropyl alcohol skin preps and sprayed with a thin layer of 20% Benzocaine (Americaine aerosol spray container) and covered with an occlusive plastic film for 10 minutes. The film was removed and the skin was cleansed with de-ionized water followed by alcohol prep. Hair removal, using an epilator machine (Remington EP 7030), was performed by clearing an area of 5x5cm or 2x2 inch square. The epilated area was then covered with a thin layer of 0.2% Sodium Lauryl Sulfate (SLS) in de-ionized water.
After each of the skin preparations and without delay, 15mg of methylcobalamin dissolved in 4mL of de-ionized water soaked into the anode patch reservoir was applied to the designated skin of the proximal anterior thighs. The 7x7cm skin area under the negative electrode was wiped with an alcohol pad and 0.5mL of 1% citric acid dissolved in 0.9% normal saline solution was applied to the negative electrode's skin contact surface. The return (negative) electrode was then attached to the skin 10cm from the positive electrode.
An elevated room temperature of 73-78 degrees Fahrenheit (25 degrees Celsius) was maintained in the room for the purposes of maintaining adequate blood flow in the peripheral dermal capillaries. No exclusion criteria for diseases that decrease capillary perfusion such as diabetes have been utilized. As a result, 2 of the 10 subjects who participated in this study had a diagnosis of Diabetes Mellitus type 2.
IBOX ION device was attached to the electrodes by way of wire leads and a multimeter was attached to the electrodes in parallel in order to record the skin's electrical resistivity prior to and after ION. Throughout the 20-minute ION session, voltage exerted by the IBOX was recorded at regular intervals. The voltage was automatically adjusted by the IBOX to deliver a pre-set constant electrical current of 4mA/minute. Throughout the procedure subjects were asked about the presence of any sensations associated with the ION including effects of the medication being administered.
- Being tested
- Vitamin B12
- Keywords
- Transdermal Penetration Enhancers, Iontophoresis, Neostigmine, Glycopyrrolate, Vitamin B12, Methylcobalamin, Cyanocobalamin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vitamin B12Dietary supplement
Also called Iontophoresis
Diffusion of Vitamin B12 through the skin over 20 minutes under the effect of low amount of direct electric current
| Study group | Role | What they receive |
|---|---|---|
| Epilation | Experimental | Hair epilated prior to application of Vitamin B12 solution to skin Receives: Dietary Supplement: Vitamin B12 |
| Oleic Acid | Experimental | Oil is allowed to soak the skin prior to application of Vitamin B12 solution to skin Receives: Dietary Supplement: Vitamin B12 |
| No Prep | Experimental | Skin is cleansed with an alcohol wipe prior to application of Vitamin B12 solution to skin Receives: Dietary Supplement: Vitamin B12 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Amount of Vitamin B12 delivered into the systemic circulation
micrograms
Measured: 20 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2019
- Study start5 Oct 2017
- Primary completion4 Oct 2018
- Study completion1 Nov 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Macrocytic Anemia With Vitamin B12 DeficiencyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Sponsor type
- US federal agency
- Responsible party
- Principal investigator, Mark A. Kortsen, MD, James J. Peters Veterans Affairs Medical Center
- Investigators
- Mark Korsten, MD, Principal investigator, Employee
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04027959
- Sponsor's protocol ID
- KOR-17-34
- Status last verified
- Dec 2020
- First submitted
- 19 Jul 2019
- Last updated
- 14 Dec 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No plan to share IPD information
Study at a glance
From the registry record, last updated by the sponsor on 14 Dec 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Novel Skin Preparation Approaches for Transdermal Delivery by Iontophoresis of a Low Molecular Weight, Positively Charged Compound (Vitamin B12) to the Systemic Circulation
- ClinicalTrials.gov ID
- NCT04027959
- Acronym / sponsor ID
- KOR-17-34
- Keywords
- Transdermal Penetration Enhancers, Iontophoresis, Neostigmine, Glycopyrrolate, Vitamin B12, Methylcobalamin, Cyanocobalamin
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- James J. Peters Veterans Affairs Medical CenterUS federal agency
- Study start
- 5 Oct 2017 (actual)
- Primary completion
- 4 Oct 2018 (actual)
- Study completion
- 1 Nov 2018 (actual)
- First posted
- 22 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
STUDY DESIGN: Phase I Clinical Trial The researchers set out to assess the effectiveness of transdermal iontophoretic administration of Vitamin B12 (V.B12) under three different skin preparatory conditions.
SETTING: James J. Peters Veterans Affairs Medical Center (Bronx, NY) BACKGROUND: Poor skin permeability precludes the use of transdermal route from being used in common clinical practice for rapid and precise administration of medications through intact skin that are expected to have a systemic effect. The researchers determined the relative effectiveness of an unconventional transdermal iontophoresis technique for the administration of Vitamin B12 (V.B12) under three different skin preparatory conditions.
METHODS: During this study, Vitamin B12 (V.B12) was administered through the skin of volunteer human research subjects. Iontophoresis was used as transdermal medication delivery modality after pre-treatment of the skin in 3 different ways. The sequence of skin preparations was arranged in a random order for each subject. Method 1 was called "No Prep", serving as the control approach; method 2 was called "Oleic Acid" application to the skin for 40 minutes; and method 3 was hair "Epilation" (e.g. hair removal by plucking). Fifteen milligrams of aqueous solution of V.B12 was administered through intact, previously unused skin of an anterior thigh during all 3 tests. Chemoluminescence, on an automated laboratory reader Advia Centaur-XP, was used to determine the serum concentration of V.B12 prior to and after transdermal iontophoretic delivery. All 3 experiments were performed on the same day within an hour of each other. The subject's blood was drawn prior and 10 minutes after the 20-minute long sessions of transdermal V.B12 iontophoresis. We were able to calculate the increase in serum V.B12 concentration and based on estimated blood volume, the total quantity and percent dose delivered systemically.
Detailed description
In order to quantify the changes in skin permeability to drugs delivered by ION under three different preparatory conditions, we used V.B12 as a model substance. Its choice was dictated by its inherent safety, positive charge and quantification of serum concentration readily available through our clinical laboratory. We compared the effects of unprepared skin (No Prep), oil-soaked skin [ref. 9-12] (Oleic Acid) and skin from which hair have been plucked out of (Epilation), on the serum concentrations of V.B12 before and after administration via ION.
Veterans and non-Veterans without SCI were recruited for the study comparing the three skin preparation methods. This prospective, skin preparatory method sequence-randomized study was approved by the Institutional Review Board of the James J. Peters VA Medical Center (JJPVAMC). The ION equipment used was a standard FDA-approved wired ION controller unit (IBOX by Dynatronics) and 4mL ION electrodes by (ionto+ by Richmar). The skin was prepared using 1 of the 3 techniques, performed in a random order. Each subject was assigned a 2-digit sequential number. A random-numbers table was used to assign the sequence of methods to each subject. A single positive electrode patch containing 4mL of a water-based solution with 15mg of V.B12 was used per experiment. One negative electrode patch was also used to complete the circuit. Blood was drawn prior to the first administration. Thirty minutes after the start of the ION delivery of the V.B12 through the skin of anterior thigh, the blood was drawn again. The blood was centrifuged for 5 minutes and delivered to the clinical laboratory for testing without delay. Serum concentration of V.B12 was measured using chemoluminescence on an automated laboratory reader Advia Centaur-XP. The experiments were conducted sequentially in a timely fashion, performed on the same day and within a span of 3 hours. Blood was drawn for a total of 4 times per subject.
The "No Prep" technique was performed by simply wiping the two skin surfaces on an anterior thigh, where the electrodes were later attached, with two-70% isopropyl alcohol prep. pads. The skin surface destined for positive electrode application was sprayed with a thin layer of 20% Benzocaine (Americaine aerosol spray can) and covered with an occlusive plastic film for 10 minutes. The film was then removed and the skin was cleansed with water-moistened paper towel, followed by one alcohol prep. pad.
The "Oleic Acid" technique involved first wiping the two skin patches and later soaking the skin patch, where the positive electrode was going to be placed, with oil called oleic acid for 40 minutes. The oil was then wiped off with a paper napkin and an alcohol pad. That same skin area was sprayed with a thin layer of 20% Benzocaine (Americaine aerosol spray container) and covered with an occlusive plastic film for 10 minutes. The film was then removed and the skin was cleansed with water-moistened paper towel, followed by one alcohol prep.
The "Hair Epilation" technique involved first wiping the two skin patches with 2-70% isopropyl alcohol skin preps and sprayed with a thin layer of 20% Benzocaine (Americaine aerosol spray container) and covered with an occlusive plastic film for 10 minutes. The film was removed and the skin was cleansed with de-ionized water followed by alcohol prep. Hair removal, using an epilator machine (Remington EP 7030), was performed by clearing an area of 5x5cm or 2x2 inch square. The epilated area was then covered with a thin layer of 0.2% Sodium Lauryl Sulfate (SLS) in de-ionized water.
After each of the skin preparations and without delay, 15mg of methylcobalamin dissolved in 4mL of de-ionized water soaked into the anode patch reservoir was applied to the designated skin of the proximal anterior thighs. The 7x7cm skin area under the negative electrode was wiped with an alcohol pad and 0.5mL of 1% citric acid dissolved in 0.9% normal saline solution was applied to the negative electrode's skin contact surface. The return (negative) electrode was then attached to the skin 10cm from the positive electrode.
An elevated room temperature of 73-78 degrees Fahrenheit (25 degrees Celsius) was maintained in the room for the purposes of maintaining adequate blood flow in the peripheral dermal capillaries. No exclusion criteria for diseases that decrease capillary perfusion such as diabetes have been utilized. As a result, 2 of the 10 subjects who participated in this study had a diagnosis of Diabetes Mellitus type 2.
IBOX ION device was attached to the electrodes by way of wire leads and a multimeter was attached to the electrodes in parallel in order to record the skin's electrical resistivity prior to and after ION. Throughout the 20-minute ION session, voltage exerted by the IBOX was recorded at regular intervals. The voltage was automatically adjusted by the IBOX to deliver a pre-set constant electrical current of 4mA/minute. Throughout the procedure subjects were asked about the presence of any sensations associated with the ION including effects of the medication being administered.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Epilation | Experimental | Dietary Supplement: Vitamin B12Hair epilated prior to application of Vitamin B12 solution to skin |
| Oleic Acid | Experimental | Dietary Supplement: Vitamin B12Oil is allowed to soak the skin prior to application of Vitamin B12 solution to skin |
| No Prep | Experimental | Dietary Supplement: Vitamin B12Skin is cleansed with an alcohol wipe prior to application of Vitamin B12 solution to skin |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Able-bodied,
- Male or female,
- Between the ages of 18-80 years old.
Key exclusion criteria (8 listed)
- Previous adverse reaction or hypersensitivity to electrical stimulation,
- Pregnancy (women who are sexually active and of childbearing potential must utilize a method of contraception and agree to maintain a contraceptive method until completion of the study),
- Inability to provide informed consent,
- History of ingrown hair folliculitis after shaving or epilation,
- Allergy to Sodium Lauryl Sulfate, Oleic acid, Silver Chloride, Agarose Gel, Methylcobalamin, Citric Acid, Isopropyl alcohol, Benzocaine, Polyethylene film, Polyethylene Glycol solvent,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vitamin B12Also: IontophoresisDiffusion of Vitamin B12 through the skin over 20 minutes under the effect of low amount of direct electric current | Dietary supplement | Epilation, No Prep, Oleic Acid |
Primary outcome
Amount of Vitamin B12 delivered into the systemic circulation
Time frame: 20 minutes
micrograms
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Dec 2020.
- Individual participant dataSharing planned: No. No plan to share IPD information
Related trials for Macrocytic Anemia With Vitamin B12 Deficiency
Active, not recruitingObservational study
Early Check: Expanded Screening in Newborns
Spinal Muscular Atrophy, Fragile X Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mark Korsten, MD principal investigator
Employee
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vitamin B12 in people with Macrocytic Anemia With Vitamin B12 Deficiency, run by James J. Peters Veterans Affairs Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Amount of Vitamin B12 delivered into the systemic circulation (time frame: 20 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Dec 2020.